652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

التفاصيل البيبلوغرافية
العنوان:	652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
المؤلفون:	Cara Haymaker, Aung Naing, Minal Barve, Marya Chaney, Se Hwan Yang, Siyoung Lee, Byung Ha Lee, Sara Ferrando-Martinez, Hirva Mamdani, Richard D Kim, Meredith Pelster, Mohamed Derbala, Jack Goon, Samuel Darko, Julie Murphy, Lauren Gorelik, Allison Bierly
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
بيانات النشر:	BMJ Publishing Group, 2023.
سنة النشر:	2023
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
العلاقة:	https://doaj.org/toc/2051-1426Test
DOI:	10.1136/jitc-2023-SITC2023.0652
الوصول الحر:	https://doaj.org/article/3834b1df978a4a97b72c5c4dae0c35d4Test
رقم الانضمام:	edsdoj.3834b1df978a4a97b72c5c4dae0c35d4
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2023-SITC2023.0652